Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Andrew McGarry(Cooper Medical School of Rowan University), Karl Kieburtz(Beth Israel Deaconess Medical Center), Corneliu Luca(University of Miami Health System), Kelvin L. Chou(Georgetown University), Kevin J. Klos(Mayo Clinic in Arizona), Ted M. Dawson(Johns Hopkins University), Sotirios A. Parashos, Jamie Chang, Jeanne Feuerstein(University of Colorado Hospital), David Shprecher(Banner Health), Shane Rosanbalm, Mitra Afshari(Rush University Medical Center), Daniel J. Burdick, Rohit Dhall(University of Arkansas for Medical Sciences), Joseph F. Quinn(Oregon Health & Science University), Arjun Tarakad(Baylor College of Medicine), C. Warren Olanow(Icahn School of Medicine at Mount Sinai), Yvette Bordelon(University of California, Los Angeles), Marie-Helene St Hiliare(Boston Medical Center), Daniel J. Lee(University of Pennsylvania), Seulki Lee(Chung-Ang University Hospital), Adam Bell(Crystal Pharmatech (United States)), Aldolfo Ramirez-Zamora(University of Florida), Viktor Roschke(Crystal Pharmatech (United States)), Mika Leinonen, Jordan Dubow, Dennis To(Crystal Pharmatech (United States)), Rajesh Pahwa(University of Kansas Medical Center)
Cited by 128
Related Papers
MDS clinical diagnostic criteria for Parkinson's disease
|Movement Disorders|2015|7.4k
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k
MDS research criteria for prodromal Parkinson's disease
|Movement Disorders|2015|1.3k
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
|New England Journal of Medicine|2009|889